Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
06
10
2022
accepted:
16
01
2023
revised:
24
12
2022
pubmed:
28
1
2023
medline:
10
3
2023
entrez:
27
1
2023
Statut:
ppublish
Résumé
Treatment of chronic myeloid leukemia has improved significantly with the introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines based on numerous clinical trials are available for chronic phase disease. However for CML in the blast phase (CML-BP), prognosis remains poor and treatment options are much more limited. The spectrum of treatment strategies for children and adolescents with CML-BP has largely evolved empirically and includes treatment principles derived from adult CML-BP and pediatric acute leukemia. Given this heterogeneity of treatment approaches, we formed an international panel of pediatric CML experts to develop recommendations for consistent therapy in children and adolescents with this high-risk disease based on the current literature and national standards. Recommendations include detailed information on initial diagnosis and treatment monitoring, differentiation from Philadelphia-positive acute leukemia, subtype-specific selection of induction therapy, and combination with tyrosine kinase inhibitors. Given that allogeneic hematopoietic stem cell transplantation currently remains the primary curative intervention for CML-BP, we also provide recommendations for the timing of transplantation, donor and graft selection, selection of a conditioning regimen and prophylaxis for graft-versus-host disease, post-transplant TKI therapy, and management of molecular relapse. Management according to the treatment recommendations presented here is intended to provide the basis for the design of future prospective clinical trials to improve outcomes for this challenging disease.
Identifiants
pubmed: 36707619
doi: 10.1038/s41375-023-01822-2
pii: 10.1038/s41375-023-01822-2
pmc: PMC9991904
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-517Informations de copyright
© 2023. The Author(s).
Références
Blood. 2014 Mar 13;123(11):1691-8
pubmed: 24366361
Acta Haematol. 2016;136(3):157-66
pubmed: 27537935
Pediatr Transplant. 2020 Jun;24(4):e13664
pubmed: 32043758
Biol Blood Marrow Transplant. 2016 Jun;22(6):1056-1064
pubmed: 26964698
Blood. 2008 Oct 15;112(8):3330-8
pubmed: 18684859
Indian J Hematol Blood Transfus. 2011 Mar;27(1):51-4
pubmed: 22379297
Blood. 2008 Aug 15;112(4):1005-12
pubmed: 18477770
J Pediatr Hematol Oncol. 2016 Nov;38(8):610-614
pubmed: 27403776
Blood. 2021 Nov 25;138(21):2031-2041
pubmed: 34407542
Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):87-92
pubmed: 24252361
Oncotarget. 2017 Dec 5;9(2):2848-2857
pubmed: 29416817
Int J Hematol. 2005 May;81(4):307-9
pubmed: 15914360
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Am J Hematol. 2019 Nov;94(11):1236-1243
pubmed: 31456269
Blood. 2022 Jan 13;139(2):305
pubmed: 35024807
Leukemia. 2018 Sep;32(9):2046-2049
pubmed: 29899367
Biol Blood Marrow Transplant. 2020 Jun;26(6):1137-1143
pubmed: 32062061
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
J Clin Oncol. 2013 Jul 1;31(19):2460-8
pubmed: 23715577
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):156-163
pubmed: 27913475
Leukemia. 2019 Aug;33(8):1910-1922
pubmed: 30858550
J Hematol Oncol. 2012 Jun 08;5:29
pubmed: 22682059
J Clin Oncol. 1997 Feb;15(2):433-44
pubmed: 9053463
Blood. 2017 May 18;129(20):2771-2781
pubmed: 28331056
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
Eur J Cancer. 2020 Sep;136:107-112
pubmed: 32668374
Biol Blood Marrow Transplant. 2019 Oct;25(10):2008-2016
pubmed: 31271884
Leuk Res. 2011 Jun;35(6):777-82
pubmed: 21145590
N Engl J Med. 2020 Oct 22;383(17):1613-1623
pubmed: 33085860
Klin Padiatr. 2009 Nov-Dec;221(6):351-7
pubmed: 19890786
Blood. 1996 Sep 15;88(6):2236-40
pubmed: 8822944
JAMA Oncol. 2020 Mar 1;6(3):358-366
pubmed: 31944221
Int J Lab Hematol. 2022 Jun;44(3):524-530
pubmed: 35315228
Br J Haematol. 2022 Dec;199(5):665-678
pubmed: 35866251
Leukemia. 2013 Jun;27(6):1254-62
pubmed: 23212150
Blood. 2016 Jan 28;127(4):392-9
pubmed: 26511135
Cancer. 2017 Nov 15;123(22):4391-4402
pubmed: 28743165
J Pediatr Hematol Oncol. 2021 Jan;43(1):e146-e147
pubmed: 31743317
Biol Blood Marrow Transplant. 2020 Mar;26(3):472-479
pubmed: 31669399
Blood. 2019 May 30;133(22):2374-2384
pubmed: 30917954
Leuk Lymphoma. 2013 Jan;54(1):138-44
pubmed: 22691121
Br J Haematol. 2020 Apr;189(2):363-368
pubmed: 31975387
Cancers (Basel). 2021 Feb 14;13(4):
pubmed: 33672937
Am J Hematol. 2021 Aug 1;96(8):1000-1007
pubmed: 33991360
Eur J Cancer. 2020 Sep;137:224-234
pubmed: 32799036
Haematologica. 2015 Mar;100(3):392-9
pubmed: 25527562
Bone Marrow Transplant. 2005 Dec;36(11):1009-15
pubmed: 16205732
Am J Hematol. 2014 Mar;89(3):282-7
pubmed: 24779033
Blood Res. 2021 Dec 31;56(4):342-345
pubmed: 34743078
Cancer Genet. 2021 Jun;254-255:70-74
pubmed: 33647814
Pediatr Blood Cancer. 2018 Dec;65(12):e27368
pubmed: 30084127
N Engl J Med. 2019 Dec 12;381(24):2315-2326
pubmed: 31826340
Am J Hematol. 2017 Jan;92(1):E3-E4
pubmed: 27727470
Cancer. 2014 Feb 1;120(3):373-80
pubmed: 24151050
J Clin Oncol. 2021 Feb 1;39(4):295-307
pubmed: 33332189
Lancet Haematol. 2018 Dec;5(12):e641-e652
pubmed: 30501871
Leuk Lymphoma. 2015 Jan;56(1):128-34
pubmed: 24712979
Leukemia. 2023 Jan;37(1):5-17
pubmed: 36309558
Br J Haematol. 2021 May;193(3):613-618
pubmed: 33690887
Blood. 2018 Aug 30;132(9):948-961
pubmed: 29967129
Br J Haematol. 2019 May;185(4):718-724
pubmed: 30843196
Hemasphere. 2020 Sep 30;4(5):e468
pubmed: 33134861
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
Nat Commun. 2021 May 14;12(1):2833
pubmed: 33990592
Leukemia. 2020 Aug;34(8):2074-2086
pubmed: 32382082
Onco Targets Ther. 2019 Dec 13;12:10989-10995
pubmed: 31997880
Transplant Cell Ther. 2021 May;27(5):427.e1-427.e7
pubmed: 33965184
Biol Blood Marrow Transplant. 2020 Mar;26(3):e55-e64
pubmed: 31557532
Hematol Oncol. 2018 Feb;36(1):344-348
pubmed: 28444777
J Hematol Oncol. 2019 Dec 5;12(1):131
pubmed: 31801582
J Clin Oncol. 2016 Aug 20;34(24):2851-7
pubmed: 27325849
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):897-901
pubmed: 28927784
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2019 Aug;33(8):1835-1850
pubmed: 31209280
Br J Haematol. 2014 Oct;167(1):33-47
pubmed: 24976289
J Clin Oncol. 2018 Aug 1;36(22):2306-2314
pubmed: 29812996
Lancet Haematol. 2022 Feb;9(2):e121-e132
pubmed: 34906334
Blood. 2018 Jul 19;132(3):264-276
pubmed: 29720486
Biol Blood Marrow Transplant. 2016 May;22(5):902-9
pubmed: 26860636
Int J Hematol. 2018 Dec;108(6):640-646
pubmed: 30078165
Bone Marrow Transplant. 2021 Nov;56(11):2834-2841
pubmed: 34331022
Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6
pubmed: 25797175
Biol Blood Marrow Transplant. 2015 Jan;21(1):184-9
pubmed: 25300870
Acta Haematol. 2005;113(3):181-9
pubmed: 15870488
Blood. 2020 Oct 8;136(15):1786-1789
pubmed: 32492706
Leukemia. 2019 May;33(5):1173-1183
pubmed: 30675008
Leukemia. 2022 Dec;36(12):2793-2801
pubmed: 35933523
Blood Cancer J. 2017 Feb 3;7(2):e521
pubmed: 28157214
Blood. 2015 May 21;125(21):3230-5
pubmed: 25852053
J Pediatr Hematol Oncol. 2016 Aug;38(6):e193-5
pubmed: 27164534
Blood. 1990 Dec 15;76(12):2462-5
pubmed: 2265242
Br J Haematol. 2013 May;161(4):541-50
pubmed: 23521501
JCO Precis Oncol. 2021 Jul 09;5:
pubmed: 34409243
Eur J Cancer. 2019 Jul;115:17-23
pubmed: 31082688
Leukemia. 2018 Jul;32(7):1657-1669
pubmed: 29925908
Immunopharmacol Immunotoxicol. 2019 Aug;41(4):490-496
pubmed: 31303072
J Clin Oncol. 2015 Apr 10;33(11):1265-74
pubmed: 25753432
Semin Hematol. 2003 Jan;40(1):59-71
pubmed: 12563612
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897